Literature DB >> 8823344

Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.

J A Lieberman1, A R Koreen, M Chakos, B Sheitman, M Woerner, J M Alvir, R Bilder.   

Abstract

For the majority of patients, schizophrenia is a chronic recurrent disease that leads to significant residual morbidity which occurs through a process of behavioral deterioration. The factors that influence the course of schizophrenia after its onset and the ability of treatment to modify the effects of the patient's illness are not well understood. This article examines specific clinical and biological variables that are associated with treatment response and outcome. These variables, which are both trait and state dependent, include premorbid adjustment, age and mode of onset of illness, gender, duration of psychosis, schizophrenia subtype, primary negative symptoms, and extrapyramidal signs including tardive dyskinesia and plasma HVA and brain pathomorphology. In addition, the chronic effects of antipsychotic drug treatment may influence illness course both favorably and adversely as well as potentially altering the neurobiological substrates that mediate expression of the illness and treatment response. Finally, the question of whether the active phase of the illness involves a pathologic process that leads to illness progression is discussed. In light of this discussion, we can speculate that although certain aspects of the illness in terms of its severity and course may be, to an extent, predetermined, a number of factors can exert favorable and unfavorable effects on the course of the illness and its ultimate outcome. One question for the field is to develop therapeutic strategies that minimize the morbidity of the illness in a way that does not introduce iatrogenic consequences to the patient.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823344

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  37 in total

1.  Treatment refractory schizophrenia.

Authors:  J P Lindenmayer
Journal:  Psychiatr Q       Date:  2000

2.  Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification.

Authors:  Saeed Farooq; Ofer Agid; George Foussias; Gary Remington
Journal:  Schizophr Bull       Date:  2013-09-17       Impact factor: 9.306

Review 3.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

4.  Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.

Authors:  D L Kelly; E Weiner; M P Ball; R P McMahon; W T Carpenter; R W Buchanan
Journal:  J Psychopharmacol       Date:  2008-06-26       Impact factor: 4.153

5.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

6.  Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria.

Authors:  Mark S Ezeme; Richard Uwakwe; Appolos C Ndukuba; Monday N Igwe; Paul C Odinka; Kennedy Amadi; Nichodemus O Obayi
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

Review 7.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 8.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Influence of duration of untreated psychosis on the short-term outcome of drug-free schizophrenia patients.

Authors:  Mariyamma Philip; Bn Gangadhar; Latha Velayudhan; D K Subbakrishna
Journal:  Indian J Psychiatry       Date:  2003-07       Impact factor: 1.759

10.  Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER.

Authors:  Michael Birnbaum; Zafar Sharif
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.